Rgenix declares Clinical and Pre-Clinical results

Clinical Biopharmaceutical Company Rgenix declared the Clinical and pre-Clinical results by research collaborators at Rgenix and Rockefeller University disclosing that Liver-X Receptor/Apolipoprotein E (LXR/ApoE) pathway controls anti-tumor immunity via effects on myeloid-derived suppressor cells (MDSCs).

MDSC’s are an immunosuppressive cell population detected to be circulating at high levels in cancer patients who are commonly found to be non-responders to immunotherapy. RGX-104 was able to deplete MDSCs both in cancer patients participating in the dose escalation portion of the Phase 1a/b trial and in mice.

Sohail Tavazoie, M.D., Ph.D., Leon Hess Associate Professor and Head of Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology at the Rockefeller University who was the senior-author of the study as well as co-founder of Rgenix, stated “The data our research has generated at this stage is exciting and supports our perspective that RGX-104 has the potential to modulate the immune response in a broad array of cancers. We will continue to progress in our research and our pursuit of unique treatments for patients affected by cancers with a high unmet medical need.”